A clinical observation to study the safety of Sidhha medicine- Arumuga Chenduram.

clinical safety evaluation of Arumuga chenduram (siddha herbo-mineral formulation)

Status

Active, not recruiting

Phases

Phase 2

Study type

Observational

Source

CTRI

Registry ID

CTRI/2020/08/026988

Enrollment

Registered

2020-08-05

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M199- Osteoarthritis, unspecified site

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Patients who taking herbo mineral drug arumuga chenduram for 48 days

Exclusion criteria

Exclusion criteria: PREGNANCY Lactation Patients with renal and liver disease Patients with cardiovascular disease Patients with gastric or peptic ulcer and GERD Patients with frequent flatulence and indigestion History of major systemic illness

Design outcomes

Primary

Measure	Time frame
To assess any changes in blood parameters and clinical symptoms during treatment, To analysis presence of mercury and iron level in bloodTimepoint: 6months	—

Secondary

Measure	Time frame
Toassess any changes in blood parameters and clinical symptoms during treatment To analysis iron and mercury level in bloodTimepoint: 6 months	—

Countries

India

Contacts

Public ContactDr R Aarthi

National institute of siddha

sppriyaathamu@gmail.com9962513101

Outcome results